NEW VISITOR POLICY in effect as of Friday, March 27
See all Novel Coronavirus Information for Penn Medicine Patients


Due to the recent Novel Coronavirus emergency, some locations may be operating with different hours or temporarily closed.

On May 1, the U.S. Food and Drug Administration approved CAR-T cell therapy developed by Penn Medicine for use in the most common form of non-Hodgkin’s lymphoma. This breakthrough means that more patients will be able to receive the potentially life-saving treatment.

Click here to read more.

Staff at the Ann B. Barshinger Cancer Institute gathered May 2 to celebrate a second FDA approval of the Penn Medicine-developed CAR-T cell therapy, this time for adult patients with non-Hodgkin’s lymphoma. 


Share This Page: